MHRA highlights drug interaction risk for hepatitis C antivirals

INR should be monitored closely in hepatitis C patients co-prescribed antivirals and vitamin K antagonists, the MHRA has advised.

INR values may fluctuate when vitamin K antagonists are co-administered with hepatitis C antivirals.  | SCIENCE PHOTO LIBRARY
INR values may fluctuate when vitamin K antagonists are co-administered with hepatitis C antivirals. | SCIENCE PHOTO LIBRARY

The MHRA advice, published in its latest , follows a Europe-wide review of the use of concomitant vitamin K antagonists (eg, warfarin) and direct-acting antivirals for hepatitis C, which reported that changes in liver function secondary to treatment with hepatitis C antivirals may affect the efficacy of vitamin K antagonists resulting in fluctutations in INR values.

Further information

View hepatitis C drug records

The MHRA states that the benefits of treatment with direct-acting antivirals for chronic hepatitis C continue to outweigh the risks of an interaction with vitamin K antagonists. However, INR should be monitored closely in patients co-prescribed these medicines and anticoagulant therapy adjusted if necessary.

Patients should be advised to inform their doctor or pharmacist if they are taking warfarin or other similar medicines and are prescribed direct-acting antivirals. Those who are taking a vitamin K antagonist should be informed that they may need more regular blood tests during treatment for hepatitis C.

Direct-acting antivirals for the treatment of chronic hepatitis C include: daclatasvir (Daklinza), dasabuvir (Exviera), ombitasvir/paritaprevir/ritonavir (Viekirax), sofosbuvir (Sovaldi), sofosbuvir/ledipasvir (Harvoni), sofosbuvir/velpatasvir (Epclusa) and simeprevir (Olysio).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

New secondary prevention approach backed for patients with stable cardiovascular disease

New secondary prevention approach backed for patients with stable cardiovascular disease

NHS prescribers have a new routine option for preventing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...